ALT Altimmune Inc.

2.15
-0.26  -11%
Previous Close 2.41
Open 2.34
Price To Book 0.48
Market Cap 18823809
Shares 8,755,260
Volume 605,574
Short Ratio
Av. Daily Volume 1,194,452

SEC filingsSee all SEC filings

  1. 8-K - Current report 181212599
  2. S-8 - Securities to be offered to employees in employee benefit plans 181211631
  3. 8-K - Current report 181211375
  4. 8-K - Current report 181203399
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181178862

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial met primary endpoint. Phase 2 planned.
HepTCell
Hepatitis B
Phase 2 additional data released September 4, 2018.
NasoVAX
Flu vaccine
Phase 1 data showed limited response.
NASOSHIELD
Anthrax

Latest News

  1. Today's Research Reports on Trending Tickers: Sage Therapeutics and Altimmune
  2. Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion
  3. Altimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  4. Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
  5. Today's Research Reports on Trending Tickers: Altimmune and Johnson & Johnson
  6. Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  7. Altimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
  8. Gaithersburg biotech CEO to step down
  9. Today’s Research Reports on Stocks to Watch: Altimmune and MannKind
  10. Why Altimmune Stock Is Sliding Lower Today
  11. Altimmune Announces $25 million Registered Direct Offering
  12. Altimmune Closes on $16.9 Million in Funding
  13. Today’s Research Reports on Stocks to Watch: Aytu Bioscience and Altimmune
  14. Altimmune Announces Pricing of $12 Million Underwritten Public Offering
  15. Altimmune Announces $4.9 million Registered Direct Offering of Common Stock
  16. Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development
  17. Today’s Research Reports on Stocks to Watch: Molecular Templates and Altimmune
  18. Why Altimmune Stock Is Skyrocketing Today

SEC Filings

  1. 8-K - Current report 181212599
  2. S-8 - Securities to be offered to employees in employee benefit plans 181211631
  3. 8-K - Current report 181211375
  4. 8-K - Current report 181203399
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181178862
  6. 8-K - Current report 181178832
  7. 8-K - Current report 181132555
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 181125355
  9. 424B5 - Prospectus [Rule 424(b)(5)] 181114387
  10. 424B5 - Prospectus [Rule 424(b)(5)] 181112457